This website focuses on chronic sialorrhea in adults, further information,
including sialorrhea in children with neurological and neurodevelopmental
disorders aged 2-17 and >12kg will be available in the future

SIALORRHEA CAN NEGATIVELY
IMPACT PATIENTS’ QUALITY
OF LIFE AND CONTRIBUTE
TO SOCIAL ISOLATION.1,2

XEOMIN® is indicated in adults for the symptomatic treatment of:

XEOMIN® (botulinum neurotoxin type A)
  • blepharospasm and hemifacial spasm,
  • cervical dystonia of a predominantly rotational form
    (spasmodic torticollis),
  • spasticity of the upper limb and
  • chronic sialorrhea due to neurological disorders in adults.

XEOMIN® (botulinum neurotoxin type A) is recommended by NICE, within its marketing authorisation, as an option for treating chronic sialorrhea caused by neurological conditions in adults. It is recommended only if the company provides it according to the commercial arrangement.3

XEOMIN® is the first and only pharmaceutical product approved for the treatment of chronic sialorrhea due to neurological disorders in adults.4

XEOMIN® showed a significant reduction in salivary flow rate5

In SIAXI, a prospective, placebo-controlled, randomised, double-blind, parallel-group phase III study (n=184), XEOMIN® demonstrated:

Significant reduction in salivary flow by up to 33% vs. placebo5

CHANGE FROM BASELINE IN uSFR
Graph showing Change From Baseline in uSFR
  • Sustained reduction of sialorrhea symptoms with repeated treatments over 64 weeks6
  • Significant improvements in patients’ perception of functioning vs. placebo5

XEOMIN® has an established tolerability and safety profile5,6

Most common treatment-emergent adverse events (TEAEs)*

TEAEs were defined as adverse events (AEs) with onset or worsening at or after the 1st injection of XEOMIN® or placebo up to and before 1st injection of extension period (EP) or in case of discontinuation before EP up to and including 16 weeks after 1st injection or date of last study visit, whichever was later. Placebo (n=36) XEOMIN® 75 U (n=74) XEOMIN® 100 U (n=74)
Percentage of patients
Fall 0 8.1 (6) 2.7 (2)
Dry mouth 0 5.4 (4) 4.1 (3)
Hypertension 2.8 (1) 2.7 (2) 4.1 (3)
Contusion 0 5.4 (4) 0
Tooth extraction 0 0 5.4 (4)
Diarrhoea 2.8 (1) 1.4 (1) 4.1 (3)
Dysphagia 0 4.1 (3) 0
Urinary tract infection 0 4.1 (3) 0

XEOMIN® is injected directly into the salivary glands providing targeted treatment of sialorrhea4

The following video gives guidance for injecting
with the use of ultrasound.

XEOMIN® videos labelled diagram

Injection Training:
Treatment of the parotid gland

Injection Training:
Treatment of the submandibular gland

Recommended dosage
by injection location4

The timing for repeat treatment should be determined based on the actual clinical need of the individual patient, and no sooner than every 16 weeks.

GLAND(S) UNITS PER SIDE TOTAL
Parotid gland(s) 30 Units 60 Units
Submandibular gland(s) 20 Units 40 Units
Total 50 Units 100 Units

Healthcare professional discussion on the treatment of adult sialorrhea with XEOMIN®

These videos are a selection taken from the launch of XEOMIN®’s indication in adult sialorrhea on
4th October 2019 and reflect the views and
opinions of healthcare professionals who
attended the launch.

Dr Donald Grosset

Dr Donald Grosset

Dr Donald Grosset is a Consultant Neurologist at the Institute of Neurological Sciences, Glasgow and Honorary Professor at the University of Glasgow. His clinical and research interests are in Parkinson’s disease and movement disorders.

Professor Chris McDermott

Professor Chris McDermott

Professor McDermott, Professor of Translational Neurology at SITraN and a Consultant Neurologist at the Sheffield Teaching Hospitals Foundation NHS Trust, regularly leads specialist MND and neuromuscular clinics in Sheffield.

Miss Katherine George

Miss Katherine George

Miss Katherine George is a Consultant Oral and Maxillofacial surgeon at Kings College Hospital, London. She specialises in conditions of the face, head and neck.

Case studies

Making a difference in sialorrhea

The following resources are available for download:

Contact us

contact form

By emailing and registering my data with Merz, I acknowledge that Merz Therapeutics may process my personal data in accordance with their privacy policy. I also acknowledge that Merz Therapeutics may use my personal data to contact me via email for marketing purposes.

What’s NEXT?

What is your goal with your patients?
Let’s take BoNT therapy to the next level, together.

NEXT logo
back to top arrow up Back to Top

THIS WEBSITE IS FOR
HEALTHCARE PROFESSIONALS ONLY

Are you a UK healthcare professional?

PLEASE CONSULT YOUR HEALTHCARE PROFESSIONAL FOR FURTHER
INFORMATION. For safety and patient information relating to
XEOMIN, please refer to the electronic Medicines Compendium website.
https://www.medicines.org.uk/emc/product/2162/pil
https://www.medicines.ie/medicines/xeomin-50-100-200-units-powder-for-solution-for-injection-34858/patient-info

Date of preparation: May 2022 M-XEO-UKI-1336

THIS WEBSITE IS FOR
XEOMIN IMPROVING SALIVA
CONTROL IN ADULTS

Would you like to explore saliva control in adult or paediatrics?

Date of preparation: May 2022 M-XEO-UKI-1336